Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Epstein–Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation

Bone Marrow Transplantation volume 31, pages 951–952 (2003)Cite this article

Access through your institution
Buy or subscribe

Epstein–Barr virus (EBV)-associated B-lymphoproliferative disorder (BLPD) in the setting of autologous stem cells transplantation (ASCT) is described mainly as case histories.1,2,3,4,5,6 The purine analogues as new treatment modalities with enhanced immunosuppressive effect have the capacity to promote EBV reactivation and transformation to lymphoproliferative disorder as recently demonstrated.7,8,9 Moreover, this risk could theoretically be even more pronounced if ASCT follows the treatment with purines. We report on two patients with CLL in whom EBV-BLPD developed after therapy with fludarabine monophosphate (Flu) and cycloclophosphamide (Cy) followed directly by ASCT. From 1998, in our department, all patients with CLL with risk factors–defined as Rai stage III–IV or adverse cytogenetics, rapid doubling time, diffuse marrow infiltration pattern—entered the study in which they were treated upfront according to the following protocol: Flu 25 mg/m2+Cy 250 mg/m2/3 days each month until morphological remission, then an attempt to mobilize PBPC by Cy 3 g/m2+G-CSF and if successful (ie >2 × 106 CD34+cells/kg harvested), the patients proceeded directly to ASCT after conditioning with Cy (50 mg/kg for four consecutive days, i.e. 200 mg/kg total dose). From 1998, 46 patients completed the protocol. Of these, 22 of them underwent ASCT. In 24 patients, the mobilization failed and they were treated with Flu–Cy only. In the group of patients who completed the whole protocol, we unexpectedly experienced clustering of two cases of EBV-BLPD. Patient 1 was a 57-year-old male diagnosed as having CLL stage I Rai in November 1996. In August 1998, disease progression was noted and because of the rapid doubling time the patient entered the Flu–Cy–ASCT protocol. Cytogenetic analyses revealed normal karyotype; EBV was seropositive. A nodular PR was attained after four cycles of Flu–Cy and 3 months later, he was successfully mobilized with the yield of 11.52 × 106 CD34+ cells/kg. High-dose Cy followed by PBSC infusion started 1 month after harvest. Haematological recovery was fast and uneventful and on restaging the attainment of complete remission according to NCI criteria10 was established. Furthermore, negative FACS and IgH rearrangement studies were consistent with immunophenotypic and molecular CR. At 5 months after ASCT, he developed progressive generalized adenomegaly and splenomegaly accompanied with fever. One cycle of CHOP chemotherapy was urgently applied because of presumed CLL relapse. However, the patient deteriorated rapidly and died on day +170. The bone marrow (BM) as well as FACS analysis showed no signs of CLL. Lymph node biopsies allowed a histological diagnosis of post-transplant lymphoproliferative disorder of polymorphic type. Immunohistochemistry studies demonstrated B-cell phenotype, monoclonality and positive stain for EBV-LMP1 (latent membrane protein; 1:25 monoclonal mouse antibody, clones CS 1-4, Dako, Glostrup, Denmark). The diagnosis of EBV-BPLD was further supported by positive PCR (DNA from PB, BM, lymph node) using different sets of primers for Epstein–Barr encoded RNA (EBER) and Epstein–Barr nuclear antigen (EBNA).11,12 At autopsy, there was no evidence of CLL and all histological findings from enlarged lymph nodes were in agreement with the diagnosis of polymorphic type of EBV-LPD.

Patient 2 was a male aged 49 years with Rai stage II CLL with a normal karyotype. Serological tests for EBV were positive. The patient was treated from March 1999 according to the protocol, and after four cycles of Flu–Cy he entered nodular PR, and 2 months after the last chemotherapy, he was successfully mobilized (2.73 × 106 CD 34+ cells/kg). High-dose chemotherapy with stem cell reinfusion was given immediately with an uneventful post-transplant period. The restaging 1 month after transplantation showed partial nodular remission, with no sign of disease in lymph nodes, spleen, and liver. At 2 months after ASCT, mediastinal and cervical adenomegaly developed abruptly. BM was negative on cytology and residual CLL nodules corresponded histologically with continuing nodular PR. Immunophenotypic analyses corroborated the presence of residual disease only. Surprisingly, lymph node biopsy showed a B-lineage LPD of monomorphic, diffuse large cell-type. An immunohistochemistry stain for EBV-LPD was inconclusive, but EBER and EBNA were again detected by PCR as in the previous case. The adenomegaly rapidly progressed to respiratory insufficiency requiring ventilatory support and the patient died on day +75 after ASCT, before the results of the tests were available. Autopsy was not performed. Serological tests for EBV in both the patients were not repeated after ASCT.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chao NJ, Berry GJ, Advani R et al. Epstein–Barr virus associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Transplantation 1993; 55: 1425–1428.

    Article  CAS  Google Scholar 

  2. Shepherd JD, Gascoyne RD, Barnett MJ et al. Polyclonal Epstein–Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 1995; 15: 639–641.

    CAS  Google Scholar 

  3. Briz M, Forez R, Regidor C et al. Epstein–Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T cell acute lymphoblastic leukemia. Br J Haematol 1998; 98: 485–487.

    Article  Google Scholar 

  4. Hauke RJ, Greiner TC, Smir BN et al. Epstein–Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Bone Marrow Transplant 1998; 21: 1271–1274.

    Article  CAS  Google Scholar 

  5. Peniket AJ, Perry AR, Williams CD et al. A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cells transplantation. Bone Marrow Transplant 1998; 22: 307–309.

    Article  CAS  Google Scholar 

  6. Lones MA, Kirov I, Said Jw et al. Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient. Bone marrow Transplant 2000; 26: 1021–1024.

    Article  CAS  Google Scholar 

  7. Niesvizky R, Zhu AX, Louie D et al. Epstein–Barr virus-associated lymphoma after treatment of macroglobulinemia with cladribine (letter) N Engl J Med 1999; 341: 55 (letter).

    Article  CAS  Google Scholar 

  8. Lazzarino M, Orlandi E, Baldanti F et al. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br J Haematol 1999; 107: 877–882.

    Article  CAS  Google Scholar 

  9. Tinchon C, Auner H, Linkesch W . EBV-associated lymphoproliferative disease after therapy with fludarabine in AML. Onkologie 2000; 23 (Suppl 7): 163 (abstract 0623).

    Google Scholar 

  10. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    CAS  Google Scholar 

  11. Tierney RJ, Steven A, Young L, Rickinson AB . Epstein–Barr virus latency in blood mononuclear cells:analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994; 68: 7374–7385.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Cinque P, Brytting M, Vago L et al. Epstein–Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 1993; 342: 398–401.

    Article  CAS  Google Scholar 

  13. Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–2325.

    Article  CAS  Google Scholar 

  14. Faye A, Van Den Abeele T, Peuchmaur M et al. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998; 352: 1285.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology and Oncology Charles University Hospital, Plzeň Pilsen, Czech Republic

    P Jindra, V Koza, V Vozobulová, K Černá, M Karas, D Lysák & M Švojgrová

  2. Sikl's Department of Pathology, Charles University Hospital, Plzeň Pilsen, Czech Republic

    L Boudová

Authors
  1. P Jindra
    View author publications

    Search author on:PubMed Google Scholar

  2. V Koza
    View author publications

    Search author on:PubMed Google Scholar

  3. L Boudová
    View author publications

    Search author on:PubMed Google Scholar

  4. V Vozobulová
    View author publications

    Search author on:PubMed Google Scholar

  5. K Černá
    View author publications

    Search author on:PubMed Google Scholar

  6. M Karas
    View author publications

    Search author on:PubMed Google Scholar

  7. D Lysák
    View author publications

    Search author on:PubMed Google Scholar

  8. M Švojgrová
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jindra, P., Koza, V., Boudová, L. et al. Epstein–Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation. Bone Marrow Transplant 31, 951–952 (2003). https://doi.org/10.1038/sj.bmt.1704026

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704026

This article is cited by

Search

Advanced search

Quick links